ImmunoCellular Therapeutics Selects Averion International Corp. To Conduct Phase II Glioblastoma Study

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a biotechnology company focused in continuance the development of novel immune-based cancer therapies (the “Company”), has announced that it has contracted with the clinical research organized being (CRO) Averion International Corp. to conduct its planned Phase II study of ICT-107, the Company’session show the way cancer-vaccine candidate for the usage of glioblastoma multiforme (GBM).

“We are working with governing regulatory and clinical experts on a study design that behest allow us to abide rigorously investigating the forcible assurance of ICT-107.”

Averion International is a Southborough, Mass.-based CRO with proven expertise in supporting global clinical trials in the place of pharmaceutical, biotechnology and curative device companies. Averion has significant oncology actual trial thwart varied treatment modalities, including approved and investigational agents in brain cancer.

Averion order have charge of the enrollment and execution of ImmunoCellular Therapeutics’ planned double-blind, placebo-controlled, 1:1 randomized Phase II study of ICT-107 in approximately 100 patients with newly diagnosed GBM. The study command be conducted in not fa from 15 clinical trial centers in the U.S. and Canada in collaboration through leading experts and opinion leaders in neuro-oncology. Enrollment of patients is expected to begin in Q4 2010 and is anticipated by the Company to be completed nearly 12 months after opening.

“Averion’s globally recognized reputation and extensive actual trial in brain cancer make it an ideal partner for us as we prepare to teach our Phase II GBM learn in the fourth quarter of this year,” said Manish Singh, Ph.D., president and CEO of ImmunoCellular Therapeutics. “We are working through ruling regulatory and clinical experts onward a reflect upon design that will allow us to continue rigorously investigating the eminently expressive promise of ICT-107.”

Gene Resnick, M.D., President of Averion’sitting Oncology Business Unit and an Averion founder, commented, “We are pleased to be collaborating with ImmunoCellular Therapeutics on its planned Phase II subject of attention. GBM is a relentlessly proceeding form of brain cancer for which safe and efficacious new treatments are vehemently needed. ImmunoCellular’s dedication to developing innovative cancer therapeutics complements our admit expertise in oncology, as well as our spectre of transforming medical innovations into improvements in healthcare.”

ImmunoCellular Therapeutics, Ltd.
Averion International

September 19 2010 07:00 am | Immune System

Comments are closed.